MetaCap

Editas Medicine Quarterly Income Statement

NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.64-0.07 (-4.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Editas Medicine revenue and earnings

In the quarter ended Sep 30, 2026, Editas Medicine generated $10.4 million in revenue, up 37.4% from the same quarter a year earlier. Editas Medicine reported a net loss of $23.4 million, compared with a loss of $25.1 million a year earlier. Operating margin was -234.3%.

Diluted earnings per share came in at -$0.15.

Summary generated from market data by MetaCap's automated system. Methodology

Editas Medicine income statement (quarterly)

Editas Medicine quarterly income statement
Quarter (USD)Q3 20262026-09-30Q2 20262026-06-30Q1 20262026-03-31Q4 20252025-12-31Q3 20252025-09-30Q2 20252025-06-30Q1 20252025-03-31Q4 20242024-12-31Q3 20242024-09-30Q2 20242024-06-30Q1 20242024-03-31Q4 20232023-12-31
Revenue10.37M11.89M2.83M24.74M7.54M3.58M4.66M30.60M61.00K513.00K1.14M60.05M
Revenue growth (YoY)+37.41%+232.31%-39.22%-19.16%+12265.57%+597.47%+310.40%-49.03%-98.86%-82.23%-88.48%+818.74%
Operating Expenses34.65M30.44M27.83M32.50M32.09M55.12M80.82M77.20M65.73M72.42M68.13M84.01M
Research & Development21.17M20.18M17.60M27.40M19.77M16.18M26.59M48.61M47.64M54.21M48.79M69.56M
Operating Income-24.28M-18.55M-25.00M-7.75M-24.55M-51.54M-76.16M-46.59M-65.67M-71.90M-66.99M-23.96M
Interest Expense005.00M0002.13M2.19M000—
Other Income (Expense)889.00K324.00K21.00K2.13M-569.00K-1.69M75.00K1.20M3.52M4.30M5.04M5.09M
Net Income-23.39M-18.23M-24.98M-5.62M-25.12M-53.23M-76.09M-45.40M-62.14M-67.61M-61.95M-18.87M
Net Income growth (YoY)————————————
EPS (Basic)-0.15-0.15-0.260.03-0.28-0.63-0.92-0.55-0.75-0.82-0.76-0.20
EPS (Diluted)-0.15-0.15-0.260.03-0.28-0.63-0.92-0.55-0.75-0.82-0.76-0.20
Shares Outstanding (Basic)153.60M119.29M97.88M—90.09M84.41M83.06M—82.49M82.31M81.94M—
Shares Outstanding (Diluted)153.60M119.29M97.88M—90.09M84.41M83.06M—82.49M82.31M81.94M—
EBITDA-23.90M-18.14M-24.52M-6.95M-23.83M-49.71M-74.25M-45.21M-64.07M-70.48M-65.58M-22.50M
Operating Margin-234.27%-156.05%-883.19%-31.34%-325.44%-1440.58%-1635.10%-152.24%-107649.18%-14016.18%-5902.29%-39.90%
Net Margin-225.69%-153.32%-882.44%-22.72%-332.98%-1487.84%-1633.49%-148.33%-101870.49%-13178.75%-5458.15%-31.43%

This table shows 12 quarterly periods of Editas Medicine's income statement, from Q3 2026 back to Q4 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow EDIT's reporting calendar. What is a income statement?

More financial data